(C) Reuters. FILE PHOTO: FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid/File Photo/File Photo/File Photo
(Reuters) – The European Medicines Agency (EMA) said on Thursday it had approved U.S. drugmaker Merck & Co Inc’s manufacturing site in West Point, Pennsylvania to make Johnson & Johnson (NYSE:JNJ)’s COVID-19 vaccine.
Earlier this year, Merck agreed to make its rival’s shot, after scrapping two of its own experimental COVID-19 vaccines.
The U.S. government at that time invoked the Defense Production Act to help equip two Merck plants to make the J&J vaccine.
The EMA said Merck’s site, to become operational immediately, was expected to support the continued supply of J&J’s COVID-19 vaccine in the European Union.
Europe approves Merck’s plant to make J&J COVID-19 vaccine
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.